Ceritinib

Phase 3

Novartis AG (NVS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in ALK-positive Non-small Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

ALK-positive Non-small Cell Lung Cancer

Clinical Trial

NCT02336451

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/6/2015

Zykadia

Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

lisinoprilPhase 3

Hypertension

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts